WALTHAM, Mass. | May 28, 2026
BostonGene announced that nine abstracts have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, showcasing the growing impact of its artificial intelligence-powered tumor and immune biology platform on cancer research and precision medicine. The accepted studies highlight how BostonGene’s advanced analytical technologies, including its Tumor Portrait® test and Kassandra™ cell deconvolution platform, are helping researchers identify novel biomarkers, predict treatment responses, understand resistance mechanisms, and improve patient stratification across multiple cancer types. Developed in collaboration with leading institutions including UT MD Anderson Cancer Center, Weill Cornell Medicine, and the Parker Institute for Cancer Immunotherapy, the research demonstrates the expanding role of AI-driven multimodal profiling in accelerating oncology drug development and personalized treatment strategies.
AI-Powered Tumor Microenvironment Analysis Advances Precision Oncology
A key focus of BostonGene’s ASCO presentations is the use of artificial intelligence to better understand the tumor microenvironment and improve patient selection for targeted therapies and immunotherapies. One featured study introduced a novel Harmonized Tumor Microenvironment (HTME) classification system, developed using machine learning and RNA sequencing data from more than 40,000 cancer samples. The AI-driven framework identified nine reproducible tumor microenvironment subtypes associated with immune activity, fibrosis, hypoxia, vascularization, and other biologically relevant features.
Researchers reported that the platform accurately predicted treatment response and progression-free survival across multiple cancer types, outperforming traditional classification approaches. Another study conducted with MD Anderson demonstrated that high TROP2 expression in anal cancer correlated strongly with immunohistochemistry findings, supporting the potential use of anti-TROP2 antibody-drug conjugates in selected patients and highlighting the utility of BostonGene’s Tumor Portrait® platform for biomarker discovery.
Blood-Based Immune Profiling Predicts Immunotherapy Response and Toxicity
Advertisement
Several studies presented by BostonGene focus on the growing importance of blood-based immune profiling for guiding immunotherapy decisions. In collaboration with the Parker Institute for Cancer Immunotherapy, researchers analyzed blood samples from more than 1,000 cancer patients receiving immune checkpoint inhibitor therapy as part of the RADIOHEAD pan-cancer cohort. Using multimodal profiling that combined RNA sequencing, flow cytometry, and machine learning models trained on more than 45,000 patient profiles, investigators identified immune signatures associated with both treatment response and severe immune-related adverse events.
The AI-powered platform successfully classified patients into responder, non-responder, and high-risk toxicity groups, demonstrating its potential to improve patient selection and treatment management. Additional research utilizing advanced T-cell receptor and B-cell receptor repertoire modeling showed superior predictive performance compared with conventional immune monitoring approaches, enabling earlier identification of patients at risk for severe adverse events while supporting more personalized immunotherapy strategies.
Collaborative Studies Reveal New Insights Across Multiple Cancer Types
BostonGene’s ASCO portfolio also includes studies spanning metastatic breast cancer, inflammatory breast cancer, biliary tract cancers, B-cell lymphomas, and metastatic invasive lobular carcinoma. Researchers at MD Anderson used BostonGene’s integrated genomic and transcriptomic profiling platform to identify clinically actionable insights in real-world metastatic breast cancer patients, helping guide treatment decisions and predict outcomes. In another study, BostonGene’s molecular profiling technologies characterized distinct angiogenic, fibrotic, and immunosuppressive tumor microenvironment features in metabolic disease-associated biliary tract cancers, providing insights into factors that may limit responses to immune checkpoint inhibitors.
Meanwhile, research conducted with Weill Cornell Medicine demonstrated that treatment with the EZH2 inhibitor tazemetostat induced systemic immune remodeling in patients with B-cell lymphoma receiving CAR-T therapy, supporting strategies aimed at enhancing treatment efficacy and durability. Collectively, these studies underscore BostonGene’s commitment to integrating AI, genomic science, and clinical research to advance precision oncology and improve outcomes for cancer patients worldwide.
Source: BostonGene press release
